The MEK inhibitor trametinib exhibits improved PFS and OS among patients who had metastatic melanoma with BRAFV600E or BRAFV600K mutation [132], indicating that MEK inhibition may represent an alternative strategy of halting the preternatural MAPK signaling in tumor. This evidence concerns the gene MAP2K7 and metastatic melanoma.